Tag: biotech
-

Forge Bellwater Incubator Adds Second Floor as Demand for Space Grows
Forge Bellwater is adding a second floor of space at its Foundry Row incubator, nearly doubling its footprint after a year-long waiting list for bench space.
-

Chamber of Commerce Convenes Employers to Tackle Hiring Pipeline Gaps
The Bellwater Chamber of Commerce convened roughly 40 employers for its quarterly summit on hiring pipeline gaps, revealing agreement on the problem but sharp disagreement on the pace of a fix.
-

Dr. Wei-Lin Tan’s Kincaid Lab Wins Federal Research Grant
Dr. Wei-Lin Tan’s Kincaid gene-therapy lab won a $3.2 million federal research grant, expanding her team even as economists warn it adds to the region’s biotech skills gap.
-

Dr. Wei-Lin Tan’s Lab Publishes Early Gene-Therapy Trial Results
Dr. Wei-Lin Tan’s Kincaid University lab published early-phase results for a second gene-therapy candidate, distinct from the research that spun out into Kestrel Biologics, showing responses in nine of twelve participants.
-

Mayor Renata Ibarra Announces Bid for Third Term
Mayor Renata Ibarra announced a bid for a third term Wednesday, pointing to falling unemployment and biotech-sector growth even as some council members say the recovery has bypassed Lowertown and Cedar Hollow.
-

Kestrel Biologics Raises $64 Million Series C, Plans Foundry Row Expansion
Kestrel Biologics, the Kincaid University biotech spinout anchoring Foundry Row’s growth, raised $64 million and plans to nearly double its Bellwater workforce, though executives say a skills gap could slow hiring.
-

Foundry Row Commercial Rents Climb as Biotech Firms Compete for Space
Foundry Row commercial rents have jumped nearly 40 percent in three years as biotech firms bid up lab space, pushing out longtime small tenants who can’t compete on price.
-

Biotech Boom Boosts City Tax Revenue, Budget Office Says
A budget office report projects nearly $11 million in additional city tax revenue driven by Foundry Row’s biotech expansion, prompting a debate over whether to save the windfall or spend it on transit, housing and workforce priorities.
-

Kestrel Biologics Hits First Clinical Trial Milestone for Lead Therapy
Kestrel Biologics says its lead gene-therapy candidate has cleared an early safety milestone in its Phase 1 trial, a result executives call validation for the Foundry Row biotech firm’s $64 million funding round.
